Article
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer - 1 Oct 2012
Reidy-Lagunes Diane L, Vakiani Efsevia, Segal Michal F, Hollywood Ellen M, Tang Laura H, Solit David B, Pietanza M Catherine, Capanu Marinela, Saltz Leonard B
Abstract excerpt
BACKGROUND: Neuroendocrine tumor (NET) cell lines frequently express both insulin-like growth factor (IGF) ligand and the cognate IGF-1 receptor (IGF-1R) and, as such, potentially depend on the activation of IGF-1R and its downstream effectors for growth and survival. Preclinical studies suggest...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.